Top Markets
#1 Threshold Network Threshold Network +59.74%
#2 TENDIES TENDIES +57.53%
#3 Cash Cat Cash Cat +20.85%
#4 OSK OSK +15.52%
#5 Magma Finance Magma Finance +13.86%
#6 Ape and Pepe Ape and Pepe +12.62%
#7 Safe Safe +12.42%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.31%
#9 Falcon Finance Falcon Finance +12.26%
#10 Storj Storj +10.41%
Coin of the day
Threshold Network Threshold Network
Settings
Language
ENGLISH
Currency
USD
Theme
Cellectis S.A. Cellectis S.A.

Cellectis S.A.

ALCLS
Rank in Stocks #17130
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and... Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Share Price
$3.56
Market Cap
$257.37M
Change (1 day)
5.26%
Change (1 year)
38.35%
Country
FR
Trade Cellectis S.A. (ALCLS)

Category

Healthcare
P/E ratio for Cellectis S.A. (ALCLS)
P/E ratio as of 2026 TTM: 0
According to Cellectis S.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Cellectis S.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.